Effectiveness of ketogenic therapy in patients with obesity and diabetes: a narrative review

Abstract

Over the past few decades, there has been a major increase in type 2 diabetes (T2D) prevalence, a long-term medical condition in which your body doesn't use insulin properly in most regions of the world. After adjusting for the impact of aging populations, diabetes prevalence in adults (85–95% T2D) almost doubled between 1980 and 2020 worldwide. Increases were more pronounced in low- and middle-income countries and in men compared to women. The aim of this study is to evaluate the performance of a very low-calories ketogenic diet (VLCKD) as an effective nutritional approach for both TD2 and obesity. A ketogenic diet (KD) positively affects blood glucose levels, body weight, glycosylated hemoglobin, neurological disorders, and plasma lipid profiles. We combined ClinicalTrials.gov data and data from PubMed from 2020 to 2022. Only published papers that met the requirements of reporting clinical trials investigating an adult sample of T2D obese patients were included. The review shows the beneficial therapeutic value of a VLCKD in the management of T2D and long-term obesity and its capacity to help achieve disease remission. Evidence from the literature underlines the need to redefine guidelines to offer a dietary and low-carb option to combat insulin resistance (IR) and related diseases.